Lymphocyte Subsets in Lung Cancer

Wesselius, Lewis; Wheaton, David L.; Manahan-Wahl, Lois J.; Sherard, Sarah L.; Taylor, Sarah; Abdou, Nabih A.

doi:10.1378/chest.91.5.725

Cited by 32 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that CD4+ T lymphocyte subpopulations (i.e. CD+CD45RA+, CD4+CD45RO+ and total CD4+ T lymphocytes) are increased by smoking (Wesselius et al 1987, Tollerud et al 1989a, b, Hashimoto et al 1990, Tollerud et al 1992, Chavance et al 1993, Tanigawa et al 1998); also, CD4+CD45RA+ T lymphocytes numbers are reported to be decreased by ageing (Paoli et al 1988). The eects of these confounding variables were controlled in the present study by means of the paired-sample t-test; on the other hand, those variables were not taken into account in the report by Moszczynski et al (1995).…”

Section: Discussionmentioning

confidence: 96%

Effects of occupational metallic mercury vapour exposure on suppressor-inducer (CD4+CD45RA+) T lymphocytes and CD57+CD16+ natural killer cells

Park

Araki

Nakata

et al. 2000

International Archives of Occupational and Environmental Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Effects of occupational metallic mercury vapour exposure on suppressor-inducer (CD4+CD45RA+) T lymphocytes and CD57+CD16+ natural killer cells

Park

Araki

Nakata

et al. 2000

International Archives of Occupational and Environmental Health

View full text Add to dashboard Cite

show abstract

“…28 In patients with advanced lung cancer, the peripheral and tumor lymphocyte counts are decreased, while levels of regulatory T cells (CD4 + ), which help suppress tumor immune surveillance, have been found at higher levels. [29][30][31][32] Immune checkpoint pathways involving the CTLA-4 or the PD-1/PD-L1 are involved in regulating T-cell responses, providing the rationale for blocking this pathway in NSCLC with antibodies against CTLA-4 and the PD-1/PD-L1 pathway. 32 Triple negative breast cancer (TNBC) is an aggressive subset of breast cancer with limited treatment options.…”

Section: Role Of Pd-1/pd-l1 Pathwaymentioning

confidence: 99%

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

2014

View full text Add to dashboard Cite

The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction and is a promising therapeutic target. The development of anti-PD-1 and anti-PD-L1 agents marks a new era in the treatment of cancer with immunotherapies. Early clinical experience has shown encouraging activity of these agents in a variety of tumors, and further results are eagerly awaited from completed and ongoing studies.

show abstract

“…KHDAK'ler içerisinde 37 hasta (%56,1) ile skuamoz hücreli akciğer kanseri birinci sıradaydı. Bu hastaların 21 İleri evre akciğer kanserli hastalarda performans durumlarının daha kötü olarak saptandığını gösteren çe-şitli çalışmalar bulunmaktadır 16,17 . Çalışmamızda evre I ve II hastalar ile evre III ve IV hastalar performans durumlarına göre incelendi ve evre III-IV hastalarda istatistiksel olarak anlamlı performans düşüklüğü saptandı.…”

Section: Bulgularunclassified

“…Bu bulgu çalışmamızla uyumludur. Çalışmamızdan farklı olarak ise Wesselius ve arkadaşları yaptıkları çalışmada hipoalbuminemi ile lenfositopeni arasında anlamlı iliş-ki gösterdiler 21 .…”

Section: Tartıșmaunclassified